AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents
News Dec 31, 2008
AVI BioPharma, Inc. has announced that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug (IND) applications filed in November for its two lead products for Marburg and Ebola virus. AVI BioPharma expects to receive written confirmation of the IND clearances from the FDA in early 2009.
AVI–6002 and AVI–6003 are novel analogs based on AVI’s PMO antisense chemistry in which anti–viral potency is enhanced by the addition of positively–charged components to the morpholino oligomer linkage.
Preclinical results of AVI–6002 and AVI–6033 demonstrated reproducible and high rates of survival in non–human primates challenged with a lethal infection of the Ebola and Marburg viruses.
Early Life-Changing Experiences Also Change Your GenesNews
Factors in early life such as maternal care influence the number and modifications of certain 'jumping genes' - a finding that ties together nature and nurture.READ MORE
Genetic Identity of Atacama "Alien" Skeleton RevealedNews
A mysterious six-inch skeleton found in the Chilean desert was thought to be the answer to extraterrestrial life. Instead, it may provide solutions to some very human questions about mutation.READ MORE